Homepage

An online resource created to inform healthcare professionals about advances in using gene-based testing for potential improvements in biopsy decisions and the selection of prostate cancer patients for active surveillance

Toggle
Background image

Updates

The use of PCA3 or TMPRSS2:ERG can substantially reduce the number of unnecessary biopsies without affecting 10-year survival

This was a decision-analysis study investigating the value of PCA3 and TMPRSS2:ERG in reducing the number of unnecessary biopsies and their impact on 10-year overall survival (OS) and 15-year cancer-specific survival (CSS). Data from a multi-centre, prospectively collected cohort of 420 men who had informative urine PCA3 and TMPRSS2:ERG scores and a history of at least 1 previous negative biopsy were used. Survival estimates were derived from previous studies and a literature review.

Read more

Download key data

Editorial Board

Picture of Prof. GL Andriole
Prof. Dr.
Gerald L.
Andriole
Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine
Urology
St. Louis, Missouri
USA
Alexandre de la Taille
Prof.
Alexandre
de la Taille
CHU Mondor
Urology
Créteil
France
Theo de Reijke
Dr.
Theo
de Reijke
Academic Medical Center
Urology
Amsterdam
Netherlands
Giorgio Gandaglia
Dr.
Giorgio
Gandaglia
Vita-Salute San Raffaele University
Urology
Milan
Italy
Alexander Govorov
Dr.
Alexander
Govorov
Moscow State University of Medicine and Dentistry
Urology
Moscow
Russia
Christian Gratzke
Prof. Dr.
Christian
Gratzke
Ludwig-Maximilians-University
Urology
Munich
Germany
Picture of Prof. Dr. Laurence Klotz
Prof. Dr.
Laurence
Klotz
University of Toronto, Sunnybrook Health Sciences Centre
Urology
Toronto
Canada
Daniel W. Lin
Prof.
Daniel W.
Lin
Institute for Prostate Cancer Research (IPCR) and University of Washington,
Urologic Oncology
Seattle
United States
Guillaume Ploussard
Dr.
Guillaume
Ploussard
St Jean Languedoc Hospital, Institut Universitaire du Cancer Toulouse
Urology and Oncology
Toulouse
France